Thomson A B, Kirdeikis P, Simon K, Zuk L, Pinchbeck B, Wasarab-Rolland D, Kersey K
Department of Medicine, University of Alberta, Edmonton, Canada.
Aliment Pharmacol Ther. 1993 Dec;7(6):649-53. doi: 10.1111/j.1365-2036.1993.tb00147.x.
This study was undertaken in nine fasting healthy volunteers to compare the effect of intravenous continuous infusion versus bolus injection of ranitidine on 12-h intragastric pH, and to compare the efficacy of these two modes of administration of pH-stat-adjusted infusion of ranitidine using the Gastrojet. Each volunteer had three study sessions with 12-h pH measurements. In the ranitidine infusion treatment arm (RAN-INF), ranitidine was continually infused intravenously using an IVAC-pump at a dose of 0.125 mg mg.kg over a 12-h period. In the ranitidine bolus treatment arm (RAN-BOL), ranitidine bolus 50 mg was given over 10 min, every 6 h. When ranitidine infusion was given by the pH stat method using the Gastrojet (RAN-JET), sufficient ranitidine was given to maintain a present value of pH > or = 5. The study was analysed with a 3 x 3 Latin square cross-over design with multiple measurements of each phase of the cross-over. No difference was found between RAN-INF and RAN-BOL in 12-h or in daytime (10.00-18.00 h) mean pH, median pH, or percentage of pH > or = 5. Using RAN-JET, 89.5% of the pH values were > or = 5., compared with 39.7% and 40.0% with RAN-INF or RAN-BOL. RAN-JET also gave higher (P < 0.05) mean and median 12-h or daytime pH values, as compared with RAN-INF or RAN-BOL. The mean doses of ranitidine given in the 12-h infusion periods were 100 mg, 109 mg and 112 mg (RAN-BOL, RAN-INF and RAN-JET, respectively). Thus, this superior inhibition of acid inhibition achieved with Gastrojet does not require higher mean doses of ranitidine. These findings cannot necessarily be applied to persons with duodenal ulcer disease or to patients in an intensive-care unit setting. However, the data do raise the possibility that much greater inhibition of acid inhibition can be achieved by individualizing the dose of ranitidine using the Gastrojet.
本研究选取了9名空腹健康志愿者,比较雷尼替丁静脉持续输注与大剂量注射对12小时胃内pH值的影响,并使用胃肠喷射器比较这两种雷尼替丁pH值调节输注给药方式的疗效。每位志愿者进行三次研究疗程,每次疗程均进行12小时的pH值测量。在雷尼替丁输注治疗组(RAN-INF)中,使用IVAC泵以0.125毫克/千克的剂量在12小时内静脉持续输注雷尼替丁。在雷尼替丁大剂量治疗组(RAN-BOL)中,每6小时在10分钟内给予50毫克雷尼替丁大剂量注射。当使用胃肠喷射器通过pH值调节法给予雷尼替丁输注(RAN-JET)时,给予足够的雷尼替丁以维持pH值≥5的当前值。本研究采用3×3拉丁方交叉设计,对交叉的每个阶段进行多次测量。在12小时或白天(10:00至18:00)的平均pH值、中位数pH值或pH值≥5的百分比方面,RAN-INF和RAN-BOL之间未发现差异。使用RAN-JET时,89.5%的pH值≥5,而RAN-INF或RAN-BOL分别为39.7%和40.0%。与RAN-INF或RAN-BOL相比,RAN-JET的12小时或白天平均pH值和中位数pH值也更高(P<0.05)。在12小时输注期内给予的雷尼替丁平均剂量分别为100毫克、109毫克和112毫克(分别为RAN-BOL、RAN-INF和RAN-JET)。因此,胃肠喷射器实现的这种更强的胃酸抑制作用并不需要更高的雷尼替丁平均剂量。这些发现不一定适用于十二指肠溃疡患者或重症监护病房的患者。然而,这些数据确实增加了通过使用胃肠喷射器个体化雷尼替丁剂量来实现更强胃酸抑制作用的可能性。